Source: IM Cannabis.
  • IM Cannabis (CSE:IMCC) applauds the new medical cannabis reforms that were announced by the Israeli Ministry of Health
  • The new regulations will remove many of the heavy regulations in the sector, making medical cannabis more accessible to patients as well as boosting export
  • Starting Dec. 29, patients in Israel with a wide range of diseases and medical conditions will no longer be required to obtain a license to receive medical cannabis
  • IM Cannabis Corp. opened trading at C$1.17 per share

IM Cannabis (CSE:IMCC) applauds the new medical cannabis reforms that were announced by the Israeli Ministry of Health.

The Israeli Ministry of Health announced the anticipated medical cannabis regulatory reform on Monday. The new regulations will remove many of the heavy regulations in the sector, making medical cannabis more accessible to patients as well as boosting export.

Starting Dec. 29, patients in Israel with a wide range of diseases and medical conditions will no longer be required to obtain a license to receive medical cannabis. Patients will receive a prescription similar to those for other prescription medications.

The company noted that the export process will be simplified, which could facilitate the export of Israeli grown cannabis to Europe, along with the associated EU-GMP certification process.

IMC’s CEO, Oren Shuster, believes this will change the face of the medical cannabis market in Israel. He said the Israeli Ministry of Health is clearly putting patient needs first, with the overhaul of the cannabis regulation.

“There are two aspects of the new reform which are particularly pertinent to our business. First, by moving from cannabis licenses to cannabis prescriptions and enabling the use of cannabis as a first-line treatment, we anticipate a significant growth in patient numbers. Second, by allowing the growers to separate the post-harvest process from the growing process, it could facilitate EU GMP certification, enabling export to Germany, the largest medical cannabis market in Europe, where we are a top 10 player,” Shuster said in a statement.

IM Cannabis Corp. is an international cannabis company supplying premium cannabis products to medical patients in Israel and Germany.

IM Cannabis Corp. opened trading at C$1.17 per share.

Join the discussion: Find out what everybody’s saying about this stock on the IM Cannabis Corp. Bullboard, and check out the rest of Stockhouse’s stock forums and message boards.

The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.


More From The Market Online
The White House.

@ the Bell: TSX recovers; markets assess Biden’s exit

The TSX bumped up in Monday trading after U.S. President Joe Biden’s weekend exit from the 2024 election race.
CrowdStrike headquarters in Silicon Valley, California.

CrowdStrike’s outage shows its scale: Why to buy the dip

CrowdStrike (NASDAQ:CRWD) offers a strong investment case, despite its 23.1 per cent dip after a faulty software update on Friday.